General MedicationsTOPICALStandard
SORILUX
CALCIPOTRIENE
Standard Dose
0.005%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SORILUX is listed in Drugs@FDA under application 022563 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient CALCIPOTRIENE Form and strength AEROSOL, FOAM;TOPICAL - 0.005% Sponsor MAYNE PHARMA Submission history Latest submission status date: 2019-11-05 00:00:00.
Structured Monograph
Clinical summary
Approval overview SORILUX is listed in Drugs@FDA under application 022563 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CALCIPOTRIENE Form and strength AEROSOL, FOAM;TOPICAL - 0.005% Sponsor MAYNE PHARMA Submission history Latest submission status date: 2019-11-05 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.